// App-Quantinova.ai

SAT0216 : DISEASE SEVERITY, COMORBID CONDITIONS, TREATMENT PATTERNS, AND FLARES IN ADULTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IN THE UNITED KINGDOM: A REAL-WORLD OBSERVATIONAL RETROSPECTIVE COHORT ANALYSIS

Researchers

Presenter

  • J. Langham

Principal Investigators

  • V. Barut

  • M. Samnaliev

  • S. Langham

  • S. Weir

  • X. Wang

  • B. Desta

  • E. R. Hammond

Medical Centers

  • Maverex Limited, Manchester, United Kingdom

  • GMA Diabetes, BioPharmaceuticals Med, AstraZeneca, Cambridge, United Kingdom

  • BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, United States of America

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Autoimmune (AI)

Disease

  • Lupus

  • Microvascular complications of diabetes 1

  • End stage renal disease

  • Renal disease

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Observational

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved